Tocilizumab and Baricitinib Mechanisms of Action

COVID-19 Pathogenesis: Late COVID-19

Joost Wiersinga W. eta al. JAMA Review 2020 doi:10.1001/jama.2020.12839
The Road to COVID-19 EUA Approval
Tocilizumab
- 1/8/2010 FDA approval for treatment of moderate to severe rheumatoid arthritis
- 8/31/2017 FDA approval for treatment of CAR T cell-induced cytokine release syndrome
- 6/24/2021 EUA authorization for COVID-19 hospitalized adults and children
Baricitinib
- 6/1/2018 FDA approval for treatment of moderate to severe rheumatoid arthritis
- 11/19/2020 EUA for baricitinib in combination with remdesivir for COVID-19 hospitalized adults and children
Tocilizumab: Key COVID-19 Trials

Baricitinib: Key COVID-19 Trial

Tocilizumab For Treatment of COVD-19

Baricitinib For Treatment of COVD-19

Baricitinib Dose Adjustments Due to Laboratory Abnormalities

Podcast: Play in new window | Download
Subscribe: Apple Podcasts | Google Podcasts | RSS | http://pharmsohard.com/